Radiology AI vendor Azra acquires rival firm focused on incidental findings

Radiology vendor Azra AI is acquiring a rival firm that is also focused on incidental findings. 

The Nashville, Tennessee, company—which offers AI to monitor radiology reports for unexpected findings—has reached a deal to buy Thynk Health for an undisclosed sum. Based in Lexington, Kentucky, Thynk produces software for managing lung cancer screening programs and related incidental imaging findings. 

Azra said the combined organizations will strive to ensure “no patient falls through the cracks between detection, diagnosis and treatment.”

"Too many important imaging findings never lead to action—a missed follow-up, a gap in communication, and a patient's early stage diagnosis becomes a late-stage one,” Daniel Weeks, CEO of Thynk Health, said in a statement April 28. "That's the problem Thynk was built to solve. Joining Azra gives us the platform depth and reach to deliver continuous, coordinated care with highly actionable data at vast scale across entire health system populations, not just individual programs.”

Combined, the two companies said their solutions are deployed across “hundreds of hospitals” and represent the “largest install base in its market segment.” They claim to process “over half a billion clinical reports and messages,” with the organization’s combination strengthening their market position in incidental findings solutions.  

Azra also operates across other specialties including pathology, cardiology and emergency medicine. Following the merger, its chief executive, John Marshall, will continue as CEO of the combined organization, while Weeks will act as chief operating officer. Both said they will maintain existing customer arrangements throughout the merger, “with no disruption to current contracts or workflows.”